Prostate

Open studies are marked with a purple background, closed studies have a grey background, studies to be opened have a white background
30021
Randomized phase II trial of Docetaxel (Taxotere) and Oblimersen vs Taxotere alone in patients with HRPC
30001
Radical Prostatectomy for Locally Advanced Prostate Cancer. A Feasibility Study.
30991
Randomized phase III step-up study on initial antiandrogen monotherapy in comparison with watchful waiting in asymptomatic T1-3 any G (any Gleason) N0 or NxM0 prostate cancer patients without local treatment with curative intent.
30972
RANDOMIZED PHASE III STUDY OF JM-216 ORAL PLATINUM PLUS PREDNISONE OR PREDNISONE ALONE IN PATIENTS WITH HORMONE REFRACTORY PROSTATE CANCER
30943
Randomized phase III trial of immediate versus deferred hormonal therapy in patients with elevated PSA after definitive treatment for localised prostate cancer
30954
Intermittent maximal androgen blockade in patients with metastatic prostate cancer : Feasibility study.
30944
Randomized phase II trial assessing Estramustine and Vinblastine combination chemotherapy vs. Estramustine alone in patients with hormone escaped progressive metastatic prostate cancer
30921
A prospective multicenter randomized study comparing Strontium89 Chloride and palliative local field radiotherapy in patients with hormonal escaped advanced prostatic cancer
30903
Phase III trial of Flutamide versus Prednisone in hormone resistant metastatic prostate cancer
30902
Phase II study of R75251 in patients with progressive, measurable, metastatic prostate cancer
30893
Phase III study comparing orchidectomy and orchidectomy + Mitomycin C in patients with metastatic prostate cancer with poor prognostic factors
30892
Phase III study comparing endocrine treatment with Flutamide or Cyproterone acetate in patients with painless metastatic prostate cancer with favorable prognostic factors
30884
Phase II protocol for the study of high dose Epirubicin in patients with progressive measurable metastatic prostate cancer
30865
A randomized phase III study comparing estracyt and mitomycin-C in hormone escaped advanced prostatic cancer
30853
Phase III protocol for a randomized prospective study of the treatment of patients with metastatic prostatic cancer to compare the therapeutic effect of orchidectomy versus LHRH-analogue depot preparation supplemented by an antiandrogen
30852
PHASE II STUDY OF Methotrexate IN PROGRESSIVE MEASURABLE PROSTATE CANCER
30843
Phase III trial of the treatment of patients with metastatic prostatic cancer to compare the therapeutic effect of orchidectomy versus LHRH-analogue supplemented by an anti-androgen
16006
 Open label phase II of MEN-10755 administered every 3 weeks in patients with progressive hormone refractory prostate cancer
22961
Long term adjuvant hormonal treatment with LHRH analogue versus no further treatment in locally advanced prostatic carcinoma treated by external irradiation and a six months combined androgen blockade - A phase III study. (Joint study of the EORTC Radiotherapy Cooperative Group and the EORTC Genito-Urinary Tract Cancer Cooperative Group)
22863
Phase III randomized clinical trial in high metastatic risk carcinoma of the prostate comparing pelvic radiotherapy plus LHRH analogue (Jointly with the EORTC Radiotherapy Cooperative Group)
30846
Phase III trial of endocrine treatment versus delayed endocrine treatment for patients with pN1-3M0 carcinoma of the prostate
22911
Phase III study of post-operative external radiotherapy in pathological stage T3N0 prostatic carcinoma (Joint study of the EORTC Radiotherapy Cooperative Group and the EORTC Genito-Urinary Tract Cancer Cooperative Group)
30891
Phase III study comparing early versus delayed orchidectomy, or early versus delayed treatment with a depot LHRH analogue (Buserelin) respectively, in patients with asymptomatic non metastatic prostate cancer T0-4 N0-2 M0
22991
Three Dimensional Conformal Radiotherapy / Intensity Modulated Radiotherapy alone vs Three Dimensional Conformal Radiotherapy / Intensity Modulated Radiotherapy plus adjuvant hormonal therapy in localized T1b-c, T2a, N0, M0 prostatic carcinoma. A Phase III Randomized Study.
30985
Intermittent androgen deprivation in patients with stage D2 prostate cancer-Phase III
22043
Post-operative external radiotherapy combined with concomitant and adjuvant hormonal treatment versus post-operative external radiotherapy alone in pathological stage pT3a-b R0-1/pT2R1 N0M0, Gleason score 5-10 prostatic carcinoma. A phase III study.

Back to Site-list